article thumbnail

FDA OKs Amvuttra To Treat Heart Conditions

Drugs.com

Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people. MONDAY, March 24, 2025 -- The U.S. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to.

FDA 279
article thumbnail

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

BioPharma Drive: Drug Pricing

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

FDA 363
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Warns of Toxic Lead in Cinnamon Products

Drugs.com

The FDA urged folks to throw away and not buy the following brands of. WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead.

FDA 364
article thumbnail

Duchenne approval exposes FDA rift over Sarepta gene therapy

BioPharma Drive: Drug Pricing

Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote.

Therapies 334
article thumbnail

Patrizia Cavazzoni, key FDA official, to leave agency

BioPharma Drive: Drug Pricing

The director of the FDA's main drug review office will exit on Jan. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming administration change. 18, according to an email sent to staff.

FDA 286
article thumbnail

FDA makes end of Zepbound, Mounjaro shortage official

BioPharma Drive: Drug Pricing

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded versions.

FDA 294
article thumbnail

FDA Approves Susvimo for Diabetic Macular Edema

Drugs.com

Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic. WEDNESDAY, Feb. 5, 2025 -- The U.S.